Extracorporeal shock wave lithotripters
This article was originally published in The Gray Sheet
Executive Summary
FDA proposed rule published Feb. 8 would reclassify the devices from Class III to Class II when intended to fragment kidney and ureteral calculi. A draft guidance released by the agency the same day would serve as a special control for the devices. According to the document, 510(k)s for lithotripters with mechanisms of action and shock wave characteristics similar to existing devices would require data from 20 patients at two sites. The stipulation is in line with a recommendation made by FDA's Gastroenterology and Urology Devices Panel in July ("The Gray Sheet" Aug. 3, 1998, p. 8)
You may also be interested in...
FDA's Retroactive Use Of PMA Data Violates FDAMA, HIMA Petition Says
FDA violated the FDA Modernization Act by applying retroactively a provision of the law relating to use of data from approved premarket approval applications, the Health Industry Manufacturers Association maintains in an Aug. 9 citizen petition.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.